title: Evaluation and management of hepatitis B virus infection in hematopoietic stem cell transplantation: before and after transplantation.
abstract: HBV infection remains a major global health problem and continues to be a common cause of liver-related morbidity and mortality in both immunocompetent and immunosuppressed individuals. Reactivation of HBV is a serious complication of chemotherapy/immunosuppressive therapy in patients with HBV infection. In this article, we aim to describe the diagnosis, prevention and management of HBV infection in allogeneic hematopoietic stem cell transplant candidates, from the pre- to post-transplant period. The data currently available suggest that all individuals with hemato-/onco-logical malignancies who undergo chemotherapy/immunosuppressive therapy should be screened for hepatotropic viruses such as HBV and HCV. HBV surface antigen-positive individuals who receive chemotherapy/immunosuppressive therapy are at considerable risk of HBV reactivation. Antiviral prophylaxis prevents HBV reactivation, decreases reactivation-related morbidity and mortality, and prevents interruptions in chemotherapy/immunosuppressive therapy in such individuals. The optimal duration of antiviral prophylaxis remains to be elucidated. The vaccination of HBV-naive recipients and their donors against HBV infection prior to transplantation plays an important role in preventing acquired HBV infection. The presence of hepatitis B surface antigen positivity is not an absolute contraindication for allogeneic hematopoietic stem cell transplantation.
authors.affiliation: Ankara University Faculty of Medicine, Department of Gastroenterology, Ibn-i Sina Hospital, Sihhiye, Ankara 06100, Turkey. idilman@medicine.ankara.edu.tr
authors.forename: Ramazan
authors.initials: R
authors.lastname: Idilman
authors.forename: Mutlu
authors.initials: M
authors.lastname: Arat
mesh_terms: D019072:Antibiotic Prophylaxis / Q000379:methods*; D000998:Antiviral Agents / Q000627:therapeutic use*; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects*; D006509:Hepatitis B / Q000150:complications / Q000276:immunology / Q000517:prevention & control* / Q000821:virology; D006515:Hepatitis B virus / Q000502:physiology*; D006801:Humans; D019259:Lamivudine / Q000627:therapeutic use; D012307:Risk Factors; D014775:Virus Activation / Q000502:physiology
chemical_list: D000998:Antiviral Agents; D019259:Lamivudine